European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novelprophylactic and therapeutic vaccine candidates


The generation of novel vaccine candidates in the field of prophylactic and therapeutic vaccines inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses (for therapeutic vaccines).


Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at an early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.

AIGHD Research Lead

Dr. Godelieve de Bree


Institut national de la santé et de la recherche médicale

Hospices Cantonaux Chuv

Sanofi Pasteur

Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer

Heinrich-Pette Institut Leibniz Institut Fuer Experimentelle Virologie

Imperial College of Science, Technology and Medicine

Istituto Superiore di Sanità

Universitaet Regensburg

Karolinska Institutet

Universitaet Zuerich

Fondazione per l’Istituto di Ricerca in Biomedicina

Universitaetsklinikum Hamburg-Eppendorf

The Chancellor, Masters and Scholars of the University of Oxford

Universite Joseph Fourier Grenoble

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Stichting Biomedical Primate Research Center

Klinkikum Der Universitat Munchen

Medizinische Universität Innsbruck

Agencia Estatal Consejo Superior De Investigaciones Cientificas

Université de Lausanne

Erasmus Universitair Medisch Centrum Rotterdam

Stichting International AIDS Vaccine Initiative

FIT Biotech Oy

EuroVacc Foundation

Fred Hutchinson Cancer Research Center

Commissariat A L Energie Atomique Et Aux Energies Alternatives

Universitaet Bern


Uganda Virus Research Institute

National Institute for Medical Research

Instituto Nacional de Saude

PACCI, University College London

The University of Liverpool

The General Hospital Corporation

Vrije Universiteit Brussel

Istituto Nazionale Malattie Infettive L.Spallanzani – IRCCS

European AIDS Treatment Group

Inserm Transfert


European Commission


France, Switzerland, Spain, Germany, UK, Italy, Sweden, Netherlands, Austria, Finland, Uganda, Tanzania, Mozambique, US, Cote d’Ivoire, Belgium